GM 102

Drug Profile

GM 102

Alternative Names: 3C23K; Anti-MISRII humanised monoclonal antibody 3C23K; GM102; Humanised monoclonal antibody 3C23K

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LFB Biotechnologies
  • Developer GamaMabs Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Anti-Mullerian hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I Gynaecological cancer

Most Recent Events

  • 06 Jun 2018 Phase-II clinical trials in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Combination therapy, Monotherapy) in Czech Republic, France (Parenteral) (EudraCT2018-000627-13)
  • 01 Jun 2018 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Gynecological cancers presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 22 May 2018 GamaMabs Pharma plans a phase II trial for Gynaecological cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top